Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.

Abstract

OBJECTIVE:

To evaluate the efficacy of 0.9% bromfenac (Xibrom™) or a celecoxib-impregnated intraocular lens (celecoxib-IOL) compared with 1% prednisolone acetate (PA) in controlling postoperative inflammation and posterior capsule opacification (PCO).

ANIMAL STUDIED:

Fifty-nine dogs undergoing cataract extraction by phacoemulsification.

PROCEDURE:

Bilateral patients received bromfenac or celecoxib-IOL plus PA in one eye, and PA in the contralateral eye. Unilateral patients received bromfenac or PA. Complete ophthalmic examination including tonometry, slit-lamp grading of flare and PCO, and digital image acquisition for masked PCO evaluation was performed within 24 h and 1, 4, 12, 24, and 56 weeks following surgery.

RESULTS:

Celecoxib-IOL/PA-treated eyes had significantly less flare than PA-treated eyes, which had significantly less flare than bromfenac-treated eyes 24 h postoperatively. There was no significant difference in intraocular pressure (IOP) postoperatively, or at 1, 24, or 56 weeks. Celecoxib-IOL/PA-treated eyes had significantly lower IOP measurements than bromfenac and PA-treated eyes at 4 and 12 weeks. There was no significant difference in PCO level between groups using slit-lamp biomicroscopy at any time point. Masked evaluation of digital images revealed significantly less PCO in celecoxib-IOL/PA- vs. bromfenac-treated eyes at 4 weeks, and in bromfenac- vs. PA-treated eyes at 56 weeks.

CONCLUSIONS:

Eyes receiving celecoxib-IOL/PA had better initial control of inflammation. Bromfenac was equally effective compared with PA in controlling inflammation. There was no association between COX-2 inhibitor administration and ocular hypertension. Celecoxib-IOL/PA-treated eyes showed better initial control of PCO (up to 12 weeks), while eyes receiving bromfenac had better long-term control of PCO (56 weeks).

• Authors: Heather L Brookshire, Robert V English, Bradley Nadelstein, Anne K Weigt, Barrett W Gift, Brian C Gilger
• Journal: Veterinary ophthalmology (Vet Ophthalmol) Vol. 18 Issue 3 Pg. 175-85 (May 2015) ISSN: 1463-5224 [Electronic] England
• PMID: 24636042 (Publication Type: Journal Article)
• Copyright: © 2014 American College of Veterinary Ophthalmologists.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Benzophenones
• Bromobenzenes
• Cyclooxygenase 2 Inhibitors
• bromfenac
• prednisolone acetate
• Prednisolone
• Celecoxib

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Benzophenones (therapeutic use)
• Bromobenzenes (therapeutic use)
• Celecoxib (administration & dosage, therapeutic use)
• Cyclooxygenase 2 Inhibitors (administration & dosage, therapeutic use)
• Dog Diseases (therapy)
• Dogs
• Inflammation (prevention & control, veterinary)
• Intraocular Pressure
• Lenses, Intraocular (veterinary)
• Phacoemulsification (adverse effects, veterinary)
• Prednisolone (administration & dosage, analogs & derivatives, therapeutic use)